Skip to content
Open access

MSRB3 promotes gastric cancer progression and immunotherapy resistance by stabilizing GPX4 to inhibit ferroptosis

Oct 2026 · Translational Oncology · Vol 74 · 0 citations · 33 references

TL;DR

MSRB3 is overexpressed and predicts poor prognosis in gastric cancer and targeting MSRB3 enhances response to anti-PD-1 immunotherapy.

Abstract

Highlights • MSRB3 is overexpressed and predicts poor prognosis in gastric cancer.• MSRB3 suppresses ferroptosis by stabilizing GPX4 protein.• MSRB3 inhibits GPX4 ubiquitination and proteasomal degradation.• MSRB3 depletion increases CD8+ T-cell infiltration in tumors.• Targeting MSRB3 enhances response to anti-PD-1 immunotherapy.

Read PDF

Similar papers

Open access Sep 2026

FJX1 drives FOLFOX resistance via PPARγ-mediated EMT and serves as a prognostic biomarker in colorectal cancer

Highlights • FJX1 is overexpressed in CRC and predicts poor patient survival.• FJX1 drives FOLFOX resistance by directly binding and activating PPARγ.• FJX1-PPARγ interaction promotes EMT, proliferation, and tumor migration.• Disrupting the FJX1-PPARγ axis with FX909 restores chemosensitivity.

M. Yang, Z. Tian, Y. Guo et al. · 0 citations
Open access Sep 2026

GMPS drives pancreatic cancer progression via suppressing DNA damage, STING activation and cellular senescence

Highlights • GMPS is a prognostic biomarker and therapeutic target in PDAC.• GMPS knockdown suppresses PDAC proliferation in organoids, and PDX models.• GMPS deficiency triggers DNA damage, G1 arrest and cellular senescence.• GMPS knockdown activates the STING‑TBK1 innate immune pathway.

Yang-Yi Li, Zi-Feng Zhang, Ding-Ru Li et al. · 0 citations
Open access Oct 2026

NR3C2 suppresses triple-negative breast cancer progression by regulating mitochondrial ROS homeostasis via NDUFB3

Highlights • NR3C2 expression is significantly decreased in triple-negative breast cancer and is associated with poor prognosis.• NR3C2 suppresses TNBC cell proliferation and migration both in vitro and in zebrafish xenograft models.• Transcriptomic analysis identifies NDUFB3 as a potential downstream target of NR3C2.•...

Hai-Hong Shi, Xiang-Rui Zeng, Qiao-Nan Guo et al. · 0 citations
Open access Sep 2026

Calcitriol alleviates ARID2-deficient gastric cancer metastasis via inhibition of the Wnt/β-catenin signaling pathway

Highlights • ARID2 mutation promotes the metastatic capability of GC.• Disruption of ARID2-VDR interaction activates Wnt/β-catenin signaling pathway.• VDR activation prevents ARID2-deficient GC metastasis by blocking nuclear β-catenin.• Calcitriol may represent a therapeutic candidate for ARID2-deficient GC metastasis.

Bi-Ying Liu, Zhao-Le Chu, Yi-Xian Fan et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.